Skip to main content
. 2020 May 11;2020:8974793. doi: 10.1155/2020/8974793

Figure 6.

Figure 6

Identification of two candidate compounds for the treatment of EC based on CMap analysis. (a) Identification of core genes from the top three enriched gene sets of the high-risk group. (b) Identification of core genes from the top three enriched gene sets of the low-risk group.